Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Aberrant BLID expression is associated with breast cancer progression

Authors: Xiaoyan Li, Peng Su, Xianqiang Liu, Xiangnan Kong, Xin Zhang, Hongyu Zhang, Qifeng Yang

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

In our previous study, we have found that BH3-like motif containing, cell death inducer (BLID) was a tumor suppressor in breast cancer, and its downregulation was correlated with both poor disease-free and overall survival. In the present study, we aimed to explore the possible role of BLID in breast cancer progression. We found that BLID was strongly expressed in all normal breast tissues, and it became lower and wreaker gradually in the progression from normal, UDH (usual ductal hyperplasia), ADH (atypical ductal hyperplasia), and DCIS (ductal carcinoma in situ) to breast cancer. Statistical analysis demonstrated significant different BLID expressions between proliferative and cancerous breast lesions. Our data suggested that loss of BLID may contribute to the progression of intraductal proliferation lesions to breast cancer. Our finding gives a new clue that BLID might be a potential indicator for progression of breast cancer in the future.
Literature
1.
2.
3.
Bai M, Agnantis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A, et al. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 2001;3:276–83.PubMedCentralCrossRefPubMed
4.
Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Mod Pathol. 2010;23 Suppl 2:S1–7.CrossRefPubMed
5.
Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ. Nuclear cytometric changes in breast carcinogenesis. J Pathol. 2001;193:33–9.CrossRefPubMed
6.
Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat. 1993;28:157–66.CrossRefPubMed
7.
Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U. Brcc2, a novel bh3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004;279:26780–8.CrossRefPubMed
8.
Cavalli LR, Santos SC, Broustas CG, Rone JD, Kasid UN, Haddad BR. Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;186:120–1.CrossRefPubMed
9.
Li X, Kong X, Wang Y, Yang Q. Brcc2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis. 2013;4:e757.PubMedCentralCrossRefPubMed
10.
Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16:2939–48.CrossRefPubMed
11.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the american joint committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.CrossRefPubMed
12.
Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, et al. 53 bp1 functions as a tumor suppressor in breast cancer via the inhibition of nf-kappab through mir-146a. Carcinogenesis. 2012;33:2593–600.CrossRefPubMed
13.
14.
Ganesan K, Acharya UR, Chua CK, Min LC, Abraham KT, Ng KH. Computer-aided breast cancer detection using mammograms: a review. IEEE Rev Biomed Eng. 2013;6:77–98.CrossRefPubMed
15.
16.
Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011;130:725–34.CrossRefPubMed
17.
Skomedal H, Helland A, Kristensen GB, Holm R, Borresen-Dale AL. Allelic imbalance at chromosome region 11q23 in cervical carcinomas. Eur J Cancer. 1999;35:659–63.CrossRefPubMed
18.
Gentile M, Ahnstrom M, Schon F, Wingren S. Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in pig8, a gene involved in p53-induced apoptosis. Oncogene. 2001;20:7753–60.CrossRefPubMed
19.
Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C. Microrna-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood b-cell precursor acute lymphoblastic leukemia. Genes Chromosom Cancer. 2010;49:682–7.CrossRefPubMed
20.
Gentile M, Olsen K, Dufmats M, Wingren S. Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival. Br J Cancer. 1999;80:843–9.PubMedCentralCrossRefPubMed
21.
Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin d1 amplification and survival. Diagn Mol Pathol. 2004;13:172–82.CrossRefPubMed
22.
Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007;67:818–26.CrossRefPubMed
23.
Cavalli LR, Noone AM, Makambi KH, Rone JD, Kasid UN, Haddad BR. Frequent loss of the BLID gene in early-onset breast cancer. Cytogenet Genome Res. 2011;135:19–24.PubMedCentralCrossRefPubMed
Metadata
Title
Aberrant BLID expression is associated with breast cancer progression
Authors
Xiaoyan Li
Peng Su
Xianqiang Liu
Xiangnan Kong
Xin Zhang
Hongyu Zhang
Qifeng Yang
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1710-x

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Review

The function of EMSY in cancer development

Research Article

OCT-1 overexpression is associated with poor prognosis in patients with well-differentiated gastric cancer

Research Article

Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis

Research Article

CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion

Research Article

ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis

Review

Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits